Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Gabriela M. Baerlocher, MD, Monika Haubitz, PhD, Oliver G. Ottmann, MD, Olatoyosi Odenike, MBBS, Alexander Roeth, MD, Michael A McDevitt, MD PhD, Ted Shih, Bart Burington, Dianne Morfeld, Neeru Batra, BS, David Snyder, MD, Elisabeth Oppliger Leibundgut, PharmD

Blood (2014) 124 (21): 408.

https://doi.org/10.1182/blood.V124.21.408.408

Published: 2014

Journal Articles

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

Gabriela M. Baerlocher, MD, Elisabeth Oppliger Leibundgut, PharmD, Christina Ayran, Martha Blaney, PharmD, Bart Burington, Ph.D, Dianne Morfeld, Olatoyosi Odenike, MD, Oliver Ottman, MD, Anita Reddy, PhD, Alexander Roeth, MD, Gary Spitzer, MD, Monic J. Stuart, MD, MPH, Srdan Verstovsek, MD, PhD, David S. Snyder, MD

Blood (2012) 120 (21): 179.

https://doi.org/10.1182/blood.V120.21.179.179

Published: 2012

Journal Articles

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

Jonathan W. Friedberg, MD, Julie M. Vose, M.D., Brad S Kahl, MD, Mark W. Brunvand, MD, Andre Goy, MD, Yvette L. Kasamon, Bart Burington, Ph.D, Jing Li, PhD, William Ho, MD, PhD, Bruce D. Cheson, MD

Blood (2009) 114 (22): 3742.

https://doi.org/10.1182/blood.V114.22.3742.3742

Published: 2009

Journal Articles

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

Blood (2009) 114 (22): 2721.

https://doi.org/10.1182/blood.V114.22.2721.2721

Published: 2009

Journal Articles

Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.

Xiaoyan Shi, Ph.D, Bart Burington, Ph.D, Tom Januario, Jeffrey T Lau, Shang-Fan Yu, Allen Ebens, Ph.D, David Dornan, Ph.D

Blood (2008) 112 (11): 1593.

https://doi.org/10.1182/blood.V112.11.1593.1593

Published: 2008

Journal Articles

A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.

John D. Shaughnessy, Jr., Fenghuang Zhan, Bart Burington, Yongsheng Huang, Ichiro Hanamura, James P. Stewart, Klaus Hollmig, Mauricio Pineda-Roman, Guido Tricot, Frits van Rhee, Maurizio Zangari, John Crowley, Bart Barlogie

Blood (2006) 108 (11): 111.

https://doi.org/10.1182/blood.V108.11.111.111

Published: 2006

Journal Articles

CKS1B, Mapping to an Amplicon on Chromosome 1q21 and over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through p27 Kip1 -Dependent and Independent Mechanisms.

Fenghuang Zhan, Simona Colla, James B. Chen, James P. Stewart, Xiaosong Wu, Yongsheng Huang, Ichiro Hanamura, Bart Burington, Shmuel Yaccoby, Joshua Epstein, Bart Barlogie, John D. Shaughnessy, Jr.

Blood (2006) 108 (11): 3408.

https://doi.org/10.1182/blood.V108.11.3408.3408

Published: 2006

Journal Articles

The molecular classification of multiple myeloma

Blood (2006) 108 (6): 2020–2028.

https://doi.org/10.1182/blood-2005-11-013458

Published: 2006

Includes: Supplemental data

Journal Articles

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Ichiro Hanamura, James P. Stewart, Yongsheng Huang, Fenghuang Zhan, Madhumita Santra, Jeffrey R. Sawyer, Klaus Hollmig, Maurizio Zangarri, Mauricio Pineda-Roman, Frits van Rhee, Federica Cavallo, Bart Burington, John Crowley, Guido Tricot, Bart Barlogie, John D. Shaughnessy, Jr

Blood (2006) 108 (5): 1724–1732.

https://doi.org/10.1182/blood-2006-03-009910

Published: 2006

Includes: Supplemental data

Journal Articles

Gene Expression Profiling (GEP) of Purified Plasma Cells at Baseline and 48hr after-Dexamethasone (D) or Thalidomide (T) Improve Outcome Predicition of Baseline GEP Alone in Patients with Multiple Myeloma (MM) Treated with Total Therapy 2 (TT2).

Bart Burington, John Shaughnessy, Bart Barlogie, Crowley John

Blood (2005) 106 (11): 502.

https://doi.org/10.1182/blood.V106.11.502.502

Published: 2005

Journal Articles

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

Madhav V. Dhodapkar, Fenghuang Zhan, Erik Rasmussen, Bart Burington, Brian Durie, John Crowley, Bart Barlogie, John Shaughnessy

Blood (2005) 106 (11): 1218.

https://doi.org/10.1182/blood.V106.11.1218.1218

Published: 2005

Journal Articles

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

Bart Barlogie, Ichiro Hanamura, Bart Burington, Erik Rasmussen, Peter Stewart, Guido Tricot, Elias Anaissie, Maurizio Zangari, Frits van Rhee, Klaus Hollmig, Teresa Milner, Joshua Epstein, John Crowley, John Shaughnessy

Blood (2005) 106 (11): 1155.

https://doi.org/10.1182/blood.V106.11.1155.1155

Published: 2005

Journal Articles

Interphase FISH-Defined Amplification of Chromosome 1q21 (AMP1q21) Identify High-Risk Subsets among Patients with Multiple Myeloma (MM) Lacking Metaphase Cytogenetic Abnormalities (CA).

John Shaughnessy, Ichiro Hanamura, Bart Burington, Jeffrey Sawyer, John Crowley, Bart Barlogie

Blood (2005) 106 (11): 623.

https://doi.org/10.1182/blood.V106.11.623.623

Published: 2005

Journal Articles

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Ichiro Hanamura, MD, Peter Stewart, PhD, Frederica Cavallo, MD, Bart Burington, MS, Erik Rasmussen, MS, John Crowley, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, MS, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2005) 106 (11): 1553.

https://doi.org/10.1182/blood.V106.11.1553.1553

Published: 2005

NARROW

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Monitoring of Calr Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses

Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results

A Phase I Study of PRO131921, a Novel Anti-CD20 Monoclonal Antibody in Patients with Relapsed/Refractory CD20 + Indolent NHL: Correlation Between Clinical Responses and AUC Pharmacokinetics.

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

Identification of a Diagnostic Gene Signature for SGN-40, Anti-CD40 Monoclonal Antibody, in Pre-Clinical NHL Models and the Role of FAS in SGN-40 Mediated Apoptosis.

A Validated Gene Expression Signature of High Risk Multiple Myeloma Is Defined by Deregulated Expression of Genes Mapping to Chromosome 1.

CKS1B, Mapping to an Amplicon on Chromosome 1q21 and over Expressed in Aggressive Disease, Regulates Multiple Myeloma Growth and Survival through p27 Kip1 -Dependent and Independent Mechanisms.

The molecular classification of multiple myeloma

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation

Gene Expression Profiling (GEP) of Purified Plasma Cells at Baseline and 48hr after-Dexamethasone (D) or Thalidomide (T) Improve Outcome Predicition of Baseline GEP Alone in Patients with Multiple Myeloma (MM) Treated with Total Therapy 2 (TT2).

Gene Expression Profiling of Bulk CD138+ Plasma Cells in Preneoplastic Gammopathy/Asymptomatic Myeloma Identifies Distinct Subsets of Patients.

Shorter Post-Relapse Survival (PRS) of Myeloma (MM) Patients Randomized to the Thalidomide (T) Arm of Total Therapy 2 (TT2) Related to Chromosome 1q21 Amplification (AMP1Q21, FISH) at Relapse.

Interphase FISH-Defined Amplification of Chromosome 1q21 (AMP1q21) Identify High-Risk Subsets among Patients with Multiple Myeloma (MM) Lacking Metaphase Cytogenetic Abnormalities (CA).

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only